Atossa Genetics (NASDAQ:ATOS) Stock Passes Below 200 Day Moving Average – Here’s What Happened

Atossa Genetics Inc. (NASDAQ:ATOS)’s stock price passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $11.56 and traded as low as $4.80. Atossa Genetics shares last traded at $4.82, with a volume of 190,410 shares.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Atossa Genetics in a report on Wednesday, January 21st. Ascendiant Capital Markets boosted their target price on Atossa Genetics from $116.25 to $120.00 and gave the stock a “buy” rating in a research report on Monday, December 8th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $95.00.

Atossa Genetics Stock Down 3.4%

The company has a fifty day simple moving average of $9.48 and a two-hundred day simple moving average of $11.56. The stock has a market capitalization of $41.55 million, a P/E ratio of -1.34 and a beta of 1.36.

Atossa Genetics (NASDAQ:ATOS) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($1.05) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($1.05). As a group, equities analysts forecast that Atossa Genetics Inc. will post -0.22 earnings per share for the current year.

Institutional Trading of Atossa Genetics

Large investors have recently bought and sold shares of the business. Y Intercept Hong Kong Ltd acquired a new position in shares of Atossa Genetics in the second quarter valued at approximately $321,000. Squarepoint Ops LLC raised its holdings in shares of Atossa Genetics by 39.9% during the third quarter. Squarepoint Ops LLC now owns 253,343 shares of the company’s stock worth $220,000 after acquiring an additional 72,235 shares during the period. JPMorgan Chase & Co. lifted its position in Atossa Genetics by 1,294.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 38,215 shares of the company’s stock valued at $33,000 after acquiring an additional 35,474 shares in the last quarter. Hudson Bay Capital Management LP bought a new stake in Atossa Genetics in the 2nd quarter valued at $26,000. Finally, Bank of America Corp DE boosted its stake in Atossa Genetics by 55.7% in the 2nd quarter. Bank of America Corp DE now owns 99,601 shares of the company’s stock worth $83,000 after purchasing an additional 35,629 shares during the period. 12.74% of the stock is owned by institutional investors.

Atossa Genetics Company Profile

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.